Seung-Woo Hong
Overview
Explore the profile of Seung-Woo Hong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
680
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koh D, Lee M, Park Y, Shin J, Kim J, Ryu Y, et al.
Cancer Immunol Res
. 2024 Jan;
12(4):491-507.
PMID: 38289363
The development of first-generation immune-checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 ushered in a new era in anticancer therapy. Although immune-checkpoint blockade therapies have shown clinical success, a substantial number of...
2.
Kim J, Koh D, Lee M, Park Y, Hong S, Shin J, et al.
Cell Death Differ
. 2023 Nov;
30(12):2491-2507.
PMID: 37926711
Recepteur d'origine nantais (RON, MST1R) is a single-span transmembrane receptor tyrosine kinase (RTK) aberrantly expressed in numerous cancers, including various solid tumors. How naturally occurring splicing isoforms of RON, especially...
3.
Park Y, Kim J, Ryu Y, Moon J, Shin Y, Kim J, et al.
Cancer Biol Ther
. 2023 Aug;
24(1):2246208.
PMID: 37621144
Significant improvement in targeted therapy for colorectal cancer (CRC) has occurred over the past few decades since the approval of the EGFR inhibitor cetuximab. However, cetuximab is used only for...
4.
Kim D, Ryu Y, Lee E, Koh D, Moon J, Jung S, et al.
Invest New Drugs
. 2022 Dec;
41(1):105-114.
PMID: 36538258
Dysregulated Wnt signaling is associated with malignant oncogenic transformation, especially in colon cancer. Recently, numerous drugs have been developed based on tumorigenesis biomarkers, thus having high potential as drug targets....
5.
Hong J, Kim D, Shin J, Ryu Y, Moon J, Koh D, et al.
Anticancer Res
. 2022 Mar;
42(4):1813-1819.
PMID: 35346999
Background/aim: Colorectal cancer is reported to have the highest mortality rate among human malignancies. Although many research results for the treatment of colorectal cancer have been reported, there is no...
6.
Park S, Ryu Y, Koh D, Hong S, Moon J, Shin J, et al.
J Cancer
. 2021 Aug;
12(18):5385-5393.
PMID: 34405001
The sodium-dependent vitamin C transporter 2 (SVCT2) surface glycoprotein regulates ascorbate accumulation in the plasma, often resulting in the induction of cancer cell death. Therefore, high expression of this gene...
7.
Lee H, Noh M, Hong S, Kim S, Kim S, Kim Y, et al.
Anticancer Res
. 2021 Mar;
41(3):1261-1269.
PMID: 33788717
Background/aim: Non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutation have been shown to have a good response to erlotinib, a receptor tyrosine kinase inhibitor of EGFR....
8.
Kim E, Koh D, Ryu Y, Park S, Hong S, Moon J, et al.
Mol Biol Rep
. 2021 Feb;
48(2):1651-1658.
PMID: 33580460
SVCT2, Sodium-dependent Vitamin C Transporter 2, uniquely transports ascorbic acid (also known as vitamin C and ascorbate) into all types of cells. Vitamin C is an essential nutrient that must...
9.
Jung Y, Park S, Kang D, Hwang S, Kang M, Hong S, et al.
Redox Biol
. 2020 Sep;
37:101716.
PMID: 32961441
The use of human mesenchymal stem cells (hMSCs) in clinical applications requires large-scale cell expansion prior to administration. However, the prolonged culture of hMSCs results in cellular senescence, impairing their...
10.
Hong S, Shin J, Moon J, Jung S, Koh D, Ryu Y, et al.
Invest New Drugs
. 2020 May;
38(6):1696-1706.
PMID: 32462369
Inhibitor of apoptosis proteins (IAPs) are overexpressed in the majority of cancers and prevent apoptosis by inhibiting caspases. IAPs have therefore attracted considerable attention as potential targets for anticancer therapy....